IPP Bureau
FDC’s chooses UFlex’ Asepto holographic packaging for Electral
By IPP Bureau - January 25, 2022
The six-layer packaging ensures that external media such as bacteria, light and air do not contaminate the liquid
Pfizer and BioNTech evaluate Omicron specific Covid-19 vaccine
By IPP Bureau - January 25, 2022
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
RaphaCure partners with Madhavbaug for cardiac healthcare services
By IPP Bureau - January 24, 2022
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
USFDA approves IND application for Allied’s cancer treatment
By IPP Bureau - January 24, 2022
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Al-Futtaim partners with TytoCare to expand digital health services
By IPP Bureau - January 24, 2022
Al-Futtaim will utilize TytoCare's TytoPro system in outpatient clinics around Dubai, providing patients with enhanced care and better access to specialists
Eplontersen granted Orphan Drug Designation in the US
By IPP Bureau - January 24, 2022
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
Omicron is now in community transmission in India: INSACOG
By IPP Bureau - January 23, 2022
The country is sixth among the most affected countries by active cases
Pfizer and OPKO update on the Biologics License Application for Somatrogon
By IPP Bureau - January 22, 2022
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
USFDA expands use of Remdesivir for Covid-19
By IPP Bureau - January 22, 2022
Previously, the use of the drug was limited to patients requiring hospitalization
Lannett receives USFDA safety review for biosimilar insulin glargine
By IPP Bureau - January 22, 2022
Go-ahead for pivotal clinical trial which is expected to commence by March
Positive top-line results for bimekizumab in second phase 3 psoriatic arthritis study
By IPP Bureau - January 22, 2022
UCB plans to submit regulatory applications in Q3 2022
Molnupiravir reduces risk of hospitalisation by 30% : Dr Shashank Joshi
By IPP Bureau - January 22, 2022
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
Sputnik V demonstrates better protection compared to Pfizer against Omicron: Study
By IPP Bureau - January 21, 2022
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
Medicines Patent Pool finalises 27 generic manufacturers to produce molnupiravir
By IPP Bureau - January 21, 2022
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Bristol Myers Squibb receives approval for Abecma in Japan
By IPP Bureau - January 21, 2022
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
